BioLineRx Ltd. Reports Third Quarter 2012 Financial Results

JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today reported its results for the third quarter ending September 30, 2012. Highlights of the Third Quarter of 2012 and Recent Developments: BL-1020 (Schizophrenia): Re-analysis of the Phase IIb EAGLE trial results indicates that BL-1020 demonstrated a significantly greater beneficial effect on cognitive function in schizophrenia patients compared to the original analysis of the study.